Urol. praxi. 2017;18(1):17-20 | DOI: 10.36290/uro.2017.005

Treatment of urinary tract infections in the era of antibiotic resistance

MUDr. Marek Štefan
Klinika infekčních nemocí 1. LF UK a ÚVN, Praha

Recently, there has been increasing prevalence of both healthcare-associated and community-acquired urinary tract infections

caused by bacteria resistant to commonly prescribed antibiotics. The article summarises the types of antibiotic resistance commonly

seen in everyday urological practice and also outlines the principles of antibiotic therapy and prevention of urinary tract

infections caused by resistant pathogens.

Keywords: urinary tract infections, beta-lactamases, ESBL, antibiotics, antimicrobial resistence

Published: March 1, 2017  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Štefan M. Treatment of urinary tract infections in the era of antibiotic resistance. Urol. praxi. 2017;18(1):17-20. doi: 10.36290/uro.2017.005.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Beneš J. Infekční lékařství. Praha: Galén 2009. 651 s.
    2. Greenwood D. Antimicrobial Drugs. Chronicle of a Twentieth Century Medical Triumph. New York: Oxford University Press 2008. 429 s. Go to original source...
    3. Pallett A, Hand K. Complicated urinary tract infections: practical solutions for the treatment of multiresistant Gram-negative bacteria. J Antimicrob Chemother 2016; 65 Suppl 3: iii25-33. Go to original source... Go to PubMed...
    4. Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001; 14: 933-951. Go to original source... Go to PubMed...
    5. Pena C, Pujol M, Ardanuy C, et al. Epidemiology and succesful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother 1998; 42: 53-58. Go to original source...
    6. van Duin D, Bonomo RA. Ceftazidime/avibactam and ceftolozane/tazobactam: second-generation ß-lactam/ß-lactamase inhibitor combinations. Clin Infect Dis 2016; 63: 234-241. Go to original source... Go to PubMed...
    7. Livermore DM. Clinical significance of beta-lactamase induction and stable derepression in gram-negative rods. Eur J Clin Microbiol 1987; 6: 439-445. Go to original source...
    8. Babic M, Hujer AM, Bonomo RA. What's new in antibiotic resistence? Focus on beta-lactamases. Drug Resist Updat 2006; 9: 142-156. Go to original source... Go to PubMed...
    9. Harris PN, Ferguson JK. Antibiotic therapy for inducible AmpC ß-lactamase-producing Gram-negative bacilli: what are the alternatives to carbapenems, quinolones and aminoglycosides? Int J Antimicrob Agents 2012; 40: 297-305. Go to original source... Go to PubMed...
    10. Walther-Rasmussen J, H?iby N. Class A carbapenemases. J Antimicrob Chemother 2007; 60: 470-482. Go to original source... Go to PubMed...
    11. Yong D, Toleman MA, Giske CG, et al. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 2009; 53: 5046-5054. Go to original source... Go to PubMed...
    12. Centers for Disease Control and Prevention (CDC). Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriacae in acute care facilities. MMWR Morb Mortal Wkly Rep 2009; 58: 256-260.
    13. Opal SM, Pop-Vicas A. Molecular mechanisms of antibiotic resistance in bacteria. In: Bennet JE, et al. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Saunders 2014: 235-251. Go to original source...
    14. FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects [online]. 2016-07-26 [cit. 2016-09-26]. Dostupný z WWW: http://www.fda.gov/Drugs/DrugSafety/ucm511530.htm.
    15. Fralick M, Macdonald EM, Gomes T, et al. Co-trimoxazole and sudden death in patients receiving inhibitors of renin-angiotensin system: population based study. BMJ 2014; 349: g6196. Go to original source... Go to PubMed...
    16. Walker E, Lyman A, Gupta K, et al. Clinical management of an increasing threat: outpatient urinary tract infections due to multidrug-resistant uropathogens. Clin Infect Dis 2016; 63: 960-965. Go to original source... Go to PubMed...
    17. Leggett JE. Aminoglycosides. In: Bennet JE, et al. Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases. Saunders 2014: 311-322.
    18. Pournaras S, Vrioni G, Neou E, et al. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay. Int J Antimicrob Agents 2011; 37: 244-247. Go to original source... Go to PubMed...
    19. Štefan M, Holub M. Ambulantní parenterální antibiotická terapie. Čas Lék Česk 2016; 155: 21-24. Go to PubMed...
    20. Žemličková H. Močová studie ATB rezistence (online). 2016-10-11 [cit. 2017-01-12]. Dostupný z WWW: http://www.szu.cz/mocova-studie-atb-rezistence.
    21. ##
    22. Fosfomycin In: Zeitschrischrift für Infektionstherapie, 2016; 37: 6-7.
    23. Wenisch JM, et al. Cefpirom plus Fosfomycin bei später Beatmung-assoziierter Pneumonie. Chemother J 2007; 16: 182-185.
    24. Lipp H-P. Albewährte Antibiotika im neuen Licht (Benzylbenicillin, Fosfomycin, Aztreonam und Colistin). Sonderdruck aus Med Monatsschr Pharm 2012; 10: 367-377.
    25. Mihailescu R, et al. High Activity of Fosfomycin and Rifampin against Methicillin-resistant Staphylococcus aureus Biofilm in Vitro and in experimental Foreign-Body Infection Model. Antimicrobial Agents and Chemotherapy; 2014; 58: 2547-2553. Go to original source... Go to PubMed...

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.